BHVN
Biohaven Ltd.NYSEHealthcare$9.80+1.87%ClosedMarket Cap: $1.04B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
22.62
P/S
0.00
EV/EBITDA
-1.46
DCF Value
$-0.55
FCF Yield
-58.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-688.9%
ROA
-171.2%
ROIC
-222.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-145.6M | $-1.21 |
| FY 2025 | $0.00 | $-738.8M | $-6.86 |
| Q3 2025 | $0.00 | $-173.4M | $-1.64 |
| Q2 2025 | $0.00 | $-198.1M | $-1.94 |
Analyst Ratings
View AllTD CowenBuy
2026-03-11HC Wainwright & Co.Neutral
2026-03-04RBC CapitalOutperform
2026-03-03RBC CapitalOutperform
2026-01-21Morgan StanleyOverweight
2026-01-06Trading Activity
Insider Trades
View AllMehta Kishandirector
SellThu Mar 19
CHILDS JOHN Wdirector
BuyMon Mar 09
Buten Matthewofficer: Chief Financial Officer
SellTue Mar 03
Gentile Kimberlyofficer: SVP, Clinical Operations
SellTue Mar 03
Clark George C.officer: VP, Chief Accounting Officer
SellTue Mar 03